Dopaminergic News and Research

RSS

Sleep benefits some Parkinson's patients

Some Parkinson's patients report that their motor function is better upon awakening in the morning, which is contrary to what would be expected after a night without medication. This phenomenon, known as sleep benefit, has been studied but no consistent variables have been found and in the last decade there has been little new research.

22 Jun 2012

Some patients with Parkinson's experience sleep benefit

21 Jun 2012

Targeting noradrenergic system combats gait freezing in Parkinson’s patients

Methylphenidate may be a useful treatment for patients with advanced Parkinson's disease receiving subthalamic nucleus stimulation who experience gait hypokinesia and freezing, show findings from a randomized trial.

14 Jun 2012

Therapy to halt symptoms in Parkinson's patients

Parkinson's disease, a disorder which affects movement and cognition, affects over a million Americans, including actor Michael J. Fox, who first brought it to the attention of many TV-watching Americans. It's characterized by a gradual loss of neurons that produce dopamine. Mutations in the gene known as DJ-1 lead to accelerated loss of dopaminergic neurons and result in the onset of Parkinson's symptoms at a young age.

3 May 2012

Dopamine linked to willingness to work for a monetary reward

A new brain imaging study has shown that an individual’s willingness to work hard to earn money is strongly influenced by the chemistry in three specific areas of the brain. Researchers claim that this could have important implications for the treatment of attention-deficit disorder, depression, schizophrenia and other forms of mental illness characterized by decreased motivation.

3 May 2012

Human study suggests biological basis for individual differences in behavior

Whether someone is a "go-getter" or a "slacker" may depend on individual differences in the brain chemical dopamine, according to new research in the May 2 issue of The Journal of Neuroscience. The findings suggest that dopamine affects cost-benefit analyses.

2 May 2012

Lauren Sciences, BGN Technologies sign licensing agreement for V-Smart- drug delivery technology

BGN Technologies, the technology transfer company for Ben-Gurion University of the Negev (BGU), has signed a licensing agreement for its V-Smart- drug delivery technology with Lauren Sciences LLC, a privately held biotechnology company in New York.

11 Apr 2012

UCB receives FDA approval for Neupro to treat idiopathic Parkinson's, RLS

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome.

3 Apr 2012

Heptares exercises exclusive option to license new A2A antagonist for CNS disorders

Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC, the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development.

20 Mar 2012

Allon advances into second phase of work in preclinical PD model

Allon Therapeutics Inc. announced today the completion of its first phase of work in a preclinical Parkinson's disease model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles.

12 Mar 2012

Dopamine therapy can boost creativity in patients with Parkinson's

Some Parkinson's Disease patients can suddenly become creative when they take dopamine therapy, producing pictures, sculptures, novels and poetry. But their new-found interests can become so overwhelming that they ignore other aspects of their everyday life, such as daily chores and social activities, according to research published in the March issue of the European Journal of Neurology.

24 Feb 2012

Parkinson’s disease gene - parkin explored: Study

Researchers at the University at Buffalo have discovered how mutations in the parkin gene cause Parkinson's disease, which afflicts at least 500,000 Americans and for which there is no cure. The results are published in the current issue of Nature Communications.

9 Feb 2012

Study to understand how brain processes information in competitive settings

Researchers have found a way to study how our brains assess the behavior - and likely future actions - of others during competitive social interactions. Their study, described in a paper in the Proceedings of the National Academy of Sciences, is the first to use a computational approach to tease out differing patterns of brain activity during these interactions, the researchers report.

7 Feb 2012

New technology helps scientists observe Parkinson's cell development

In the US alone, at least 500,000 people suffer from Parkinson's disease, a neurological disorder that affects a person's ability to control his or her movement. New technology from the University of Bonn in Germany lets researchers observe the development of the brain cells responsible for the disease.

1 Feb 2012

Scientists evaluate growth, differentiation and function of iPSC-derived NPCs in PD

Induced pluripotent stem cells (iPSC) are a promising avenue for cell replacement therapy in neurologic diseases. For example, mouse and human iPSCs have been used to generate dopaminergic (DA) neurons that improve symptoms in rat Parkinson's disease models. Reporting in the current issue of the Journal of Parkinson's Disease, a group of scientists from Japan evaluated the growth, differentiation, and function of human-derived iPSC-derived neural progenitor cells (NPCs) in a primate model, elucidating their therapeutic potential.

25 Jan 2012

Alexithymia associated with depression in de novo PD patients

Alexithymia has been found to be strongly associated with depression in both general and clinical populations. Alexithymic and depressive symptoms may be partially overlapping, but not all are correlated with depressive symptoms, thus underlining the relative independence of the two disorders. Parkinson's disease (PD) is a clinical condition often characterized by depression and an altered emotional processing. In medicated PD patients alexithymia has a prevalence of 21% and is related to depression.

23 Jan 2012

Amarantus receives U.S. patent titled, 'Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof'

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced U.S. Patent Number 8,084,425 has been issued for MANF entitled, Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof.

12 Jan 2012

Study finds no support for primary pathogenic role of LBs in PD

The pathology of Parkinson's disease is characterized by a loss of dopamine-producing neurons in the pars compacta of the substantia nigra (SN), an area of the brain associated with motor control, along with the development of α-synuclein (αS) protein in the form of Lewy bodies (LB) in the neurons that survive. The spread of LB pathology is thought to progress along with the clinical course of Parkinson's disease, although recent studies suggest that they are not the toxic cause of cell death.

10 Jan 2012

Stabilizing mitochondria protects against Parkinson's in a rat model

Stabilizing the cell's power-generating center protects against Parkinson's disease (PD) in a rat model, according to a report published online this week in the Journal of Experimental Medicine.

20 Dec 2011

Researchers convert astrocytes directly into dopamine-producing neurons

In efforts to find new treatments for Parkinson's Disease (PD), researchers from the Perelman School of Medicine at the University of Pennsylvania have directly reprogrammed astrocytes, the most plentiful cell type in the central nervous system, into dopamine-producing neurons.

14 Dec 2011